| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LPAR5 |
| Uniprot No | Q9H1C0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-372aa |
| 活性数据 | MLANSSSTNSSVLPCPDYRPTHRLHLVVYSLVLAAGLPLNALALWVFLRALRVHSVVSVYMCNLAASDLLFTLSLPVRLSYYALHHWPFPDLLCQTTGAIFQMNMYGSCIFLMLINVDRYAAIVHPLRLRHLRRPRVARLLCLGVWALILVFAVPAARVHRPSRCRYRDLEVRLCFESFSDELWKGRLLPLVLLAEALGFLLPLAAVVYSSGRVFWTLARPDATQSQRRRKTVRLLLANLVIFLLCFVPYNSTLAVYGLLRSKLVAASVPARDRVRGVLMVMVLLAGANCVLDPLVYYFSAEGFRNTLRGLGTPHRARTSATNGTRAALAQSERSAVTTDATRPDAASQGLLRPSDSHSLSSFTQCPQDSAL |
| 分子量 | 41.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人LPAR5蛋白的3-4条模拟参考文献(根据领域研究热点虚构，供参考)：
---
1. **文献名称**: *"Expression and functional characterization of recombinant human LPAR5 in cancer cell signaling"*
**作者**: Zhang Y et al. (2022)
**摘要**: 本研究通过杆状病毒表达系统成功制备了重组人LPAR5蛋白，并证明其在HEK293细胞中过表达后通过激活Rho/ROCK通路促进结直肠癌细胞的侵袭迁移能力，为靶向LPAR5的抗肿瘤药物开发提供实验依据。
---
2. **文献名称**: *"Structural insights into LPAR5 activation by lipid agonists via cryo-EM"*
**作者**: Wang H et al. (2021)
**摘要**: 利用冷冻电镜技术解析了重组人LPAR5蛋白与其天然配体溶血磷脂酸(LPA)结合的复合物三维结构，揭示了LPAR5特异性结合LPA的氨基酸位点及下游G蛋白偶联机制，为设计选择性受体调节剂奠定结构基础。
---
3. **文献名称**: *"LPAR5 regulates inflammatory responses in macrophages through recombinant protein-mediated NF-κB activation"*
**作者**: Lee S et al. (2020)
**摘要**: 通过构建重组人LPAR5真核表达载体，发现其在小鼠巨噬细胞中通过配体依赖性方式激活NF-κB通路，加剧脂多糖诱导的炎症因子释放，提示LPAR5可能是炎症性疾病的新型治疗靶点。
---
4. **文献名称**: *"High-yield purification of recombinant human LPAR5 for biochemical assay development"*
**作者**: Müller R et al. (2019)
**摘要**: 报道了一种基于昆虫细胞表达系统的重组人LPAR5蛋白高效纯化工艺，获得的蛋白纯度>95%，并验证其在体外结合实验中对LPA的高亲和力(Kd=12.3 nM)，可用于高通量药物筛选平台的建立。
---
注：以上文献信息为模拟生成，实际研究中请通过PubMed、Web of Science等平台检索真实发表的论文。
Lysophosphatidic acid receptor 5 (LPAR5), also known as GPR92 or GPR93. is a G protein-coupled receptor (GPCR) that binds lysophosphatidic acid (LPA), a bioactive lipid mediator involved in diverse physiological and pathological processes. LPAR5 is broadly expressed in tissues, including the immune system, nervous system, and gastrointestinal tract. It regulates cellular functions such as proliferation, migration, and calcium signaling through Gq/11 and G12/13 pathways. Dysregulation of LPAR5 has been implicated in inflammatory diseases, fibrosis, and cancer progression.
Recombinant human LPAR5 protein is engineered for in vitro studies to elucidate its structural characteristics, ligand interactions, and downstream signaling mechanisms. Produced via mammalian or bacterial expression systems, the purified protein retains functional extracellular domains critical for ligand binding. Researchers utilize it in binding assays, drug screening, and structural biology (e.g., crystallography) to develop LPAR5-targeted therapies. Its recombinant form enables controlled experimentation, aiding the exploration of LPAR5’s role in disease models and potential therapeutic modulation. Current research focuses on designing antagonists or agonists to modulate LPAR5 activity in conditions like inflammatory bowel disease or metastatic cancers.
×
